Helsinki, Finland

Nexstim is a targeted neuro-modulation company that has developed a proprietary navigated rTMS platform for use in diagnostics (NBS) and therapeutics (NBT). NBS is used in planning brain surgery while NBT is focused on depression and chronic pain. FDA approval for depression was given in 2017, and the focus is on commercial roll out in the US, Europe and Asia.

Investment Perspective

Nexstim has successfully secured funding to enable the commercialisation of its proprietary Navigated Brain Therapy (NBT) platform in MDD (major depressive disorder). The near-term challenges now shift to maximising the uptake of NBT in specialist centres in North America and Europe. Initial indications are encouraging, with notable support from major centres and key opinion leaders. Our valuation and financial models have been updated to reflect the capital raise. We value Nexstim at €18.8m or €0.53 per share (€0.40 diluted), against €35.5m, or €1.00/share (€0.73/share diluted) were the remaining financial risks removed.

Market information

SymbolPrimary exchangeCurrency
NXTMHFirst North HelsinkiEUR
Last PriceMarket Cap
52 Week Low52 Week High


Getting back on the front foot
Update | 21 May 2019
Terms of the rights issue announced
Lighthouse | 28 Mar 2019
Securing the commercial future of NBT in depression
Update | 18 Mar 2019

Recent News

Second NBT system ordered by Island Psychiatry
03 Jul 2019
Wings for Life Foundation funding for Finnish spinal cord injury rehabilitation research using SmartFocus technology
26 Jun 2019
Positive feedback from leading Austrian clinic on its first NBT system
18 Jun 2019
Amendment of stock option programmes
10 Jun 2019